Fontan术后单心室患者的长期结局:移植无生存与心功能变化
该多中心纵向研究在Fontan横断面研究(Fontan 1)后9.4±0.4年复评466例可联系患者中的373例(80%),年龄21.2±3.5岁。配对测试显示峰值摄氧量占预计值百分比、射血分数下降,B型利钠肽升高;12年间无移植生存率90%,且与心室形态无关,运动能力下降与功能健康状态较差相关。
要点
- Fontan术后12年无移植生存率90%,与心室形态无关。
- 配对随访中峰值摄氧量、射血分数下降,B型利钠肽升高。
- 运动能力较差与功能健康状态较差相关。
核心结论
- 该Fontan队列12年间无移植生存率为90%,且与心室形态无关。
- 运动能力下降并与功能健康状态较差相关。
研究设计与样本
- 多中心纵向随访研究,在Fontan横断面研究(Fontan 1)后9.4±0.4年重复评估。
- 原队列546例中466例再次联系,373例(80%)入组,年龄21.2±3.5岁。
- 评估包括运动试验、超声心动图、B型利钠肽、功能健康评估和病史摘录。
- 采用Cox回归分析 interim 死亡或心脏移植的危险因素。
主要发现
- 配对测试中峰值摄氧量占预计值百分比下降(69±14% vs. 61±16%;p<0.001;n=95)。
- 配对测试中射血分数下降(58±11% vs. 55±10%;p<0.001;n=259)。
- 配对测试中B型利钠肽升高(中位数[四分位距] 13[7至25] pg/mol vs. 18[9至36] pg/mol;p<0.001;n=340)。
- 最新随访时较低的儿科生活质量量表身体总结评分与较差的运动表现相关(校正R2=0.20;p<0.001;n=274)。
- 自Fontan手术以来累积并发症包括再次心脏手术(32%)、导管介入(62%)、心律失常治疗(32%)、血栓(12%)和蛋白丢失性肠病(8%)。
关键数值与推荐
- 自Fontan 1以来,54例(10%)受试者接受心脏移植(n=23)或未移植死亡(n=31)。
- 间期死亡或心脏移植风险与Fontan 1时较差的心室表现和功能健康状态相关,但与心室形态、受试者年龄或Fontan连接类型无关。
临床怎么用
- Fontan术后长期随访应关注运动能力下降和功能健康状态恶化。
- 心室表现和功能健康状态可帮助识别间期死亡或心脏移植风险较高的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multicenter longitudinal objective data for survival into adulthood of patients who have undergone Fontan procedures are lacking. OBJECTIVES: This study sought to describe transplant-free survival and explore relationships between laboratory measures of ventricular performance and functional status over time. METHODS: Exercise testing, echocardiography, B-type natriuretic peptide, functional health assessment, and medical history abstraction were repeated 9.4 ± 0.4 years after the Fontan Cross-Sectional Study (Fontan 1) and compared with previous values. Cox regression analysis explored risk factors for interim death or cardiac transplantation. RESULTS: From the original cohort of 546 subjects, 466 were contacted again, and 373 (80%) were enrolled at 21.2 ± 3.5 years of age. Among subjects with paired testing, the percent predicted maximum oxygen uptake decreased (69 ± 14% vs. 61 ± 16%; p < 0.001; n = 95), ejection fraction decreased (58 ± 11% vs. 55 ± 10%; p < 0.001; n = 259), and B-type natriuretic peptide increased (median [interquartile range] 13 [7 to 25] pg/mol vs. 18 [9 to 36] pg/mol; p < 0.001; n = 340). At latest follow-up, a lower Pediatric Quality of Life Inventory physical summary score was associated with poorer exercise performance (R2 adjusted = 0.20; p < 0.001; n = 274). Cumulative complications since the Fontan procedure included additional cardiac surgery (32%), catheter intervention (62%), arrhythmia treatment (32%), thrombosis (12%), and protein-losing enteropathy (8%). Since Fontan 1, 54 subjects (10%) have received a heart transplant (n = 23) or died without transplantation (n = 31). The interval risk of death or/cardiac transplantation was associated with poorer ventricular performance and functional health status assessed at Fontan 1, but it was not associated with ventricular morphology, the subject's age, or the type of Fontan connection. CONCLUSIONS: Interim transplant-free survival over 12 years in this Fontan cohort was 90% and was independent of ventricular morphology. Exercise performance decreased and was associated with worse functional health status. Future interventions might focus on preserving exercise capacity. (Relationship Between Functional Health Status and Ventricular Performance After Fontan-Pediatric Heart Network; NCT00132782).
引用
- Atz AM, Zak V, Mahony L, et al. Longitudinal Outcomes of Patients With Single Ventricle After the Fontan Procedure. J Am Coll Cardiol. 2017. PMID: 28571639. doi:10.1016/j.jacc.2017.03.582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。